Iomab-B Single Agent Activity: 2019 SOHO Annual Meeting Honorable Distinction Award Recipient Sep 23, 2019
225Ac-CD38 Antibody Targeting is Effective and Well Tolerated in Experimental Models of Lymphoma and Multiple Myeloma Jun 25, 2019
Targeted Lymphodepletion with Radiolabeled CD45 antibody as a Preparative Regimen Prior to Adoptive Cell Therapy Jun 24, 2019
Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial. Jun 4, 2019
Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy for CAR-T Feb 20, 2019
![Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.](https://d1io3yog0oux5.cloudfront.net/_91f6f66c5dcd7ce415d986491fe50e46/actiniumpharma/db/206/925/pdf_thumbnail.jpg "Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.")
